SG11201901716TA - Adenovirus armed with bispecific t cell engager (bite) - Google Patents
Adenovirus armed with bispecific t cell engager (bite)Info
- Publication number
- SG11201901716TA SG11201901716TA SG11201901716TA SG11201901716TA SG11201901716TA SG 11201901716T A SG11201901716T A SG 11201901716TA SG 11201901716T A SG11201901716T A SG 11201901716TA SG 11201901716T A SG11201901716T A SG 11201901716TA SG 11201901716T A SG11201901716T A SG 11201901716TA
- Authority
- SG
- Singapore
- Prior art keywords
- enad
- psioxus
- international
- house
- virus
- Prior art date
Links
- 241000701161 unidentified adenovirus Species 0.000 title abstract 3
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 4
- 241000700605 Viruses Species 0.000 abstract 4
- 239000003814 drug Substances 0.000 abstract 3
- 229950002830 enadenotucirev Drugs 0.000 abstract 3
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 210000002865 immune cell Anatomy 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/761—Adenovirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/521—Chemokines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/521—Chemokines
- C07K14/522—Alpha-chemokines, e.g. NAP-2, ENA-78, GRO-alpha/MGSA/NAP-3, GRO-beta/MIP-2alpha, GRO-gamma/MIP-2beta, IP-10, GCP-2, MIG, PBSF, PF-4, KC
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7156—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interferons [IFN]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C12N15/861—Adenoviral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/90—Fusion polypeptide containing a motif for post-translational modification
- C07K2319/92—Fusion polypeptide containing a motif for post-translational modification containing an intein ("protein splicing")domain
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/60—Vector systems having a special element relevant for transcription from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/44—Vectors comprising a special translation-regulating system being a specific part of the splice mechanism, e.g. donor, acceptor
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 08 March 2018 (08.03.2018) WIPO I PCT ill IIIIIl °million °nolo otiminumo oimIE (10) International Publication Number WO 2018/041827 Al No T-cells added Uninfected EnAd EnAd-CMV-ControlBiTE EnAd-CMV-EpCAMBiTE EnAd-SA-ControlBiTE EnAd-SA-EpCAMBiTE (51) International Patent Classification: A61K 39/395 (2006.01) C07K 16/30 (2006.01) A61K 35/761 (2015.01) C07K 16/40 (2006.01) C07K 16/28 (2006.01) C12N 15/861 (2006.01) (21) International Application Number: PCT/EP2017/071655 (22) International Filing Date: 29 August 2017 (29.08.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 1614607.8 29 August 2016 (29.08.2016) GB 1700663.6 13 January 2017 (13.01.2017) GB 1706219.1 19 April 2017 (19.04.2017) GB 1713765.4 28 August 2017 (28.08.2017) GB (71) Applicant: PSIOXUS THERAPEUTICS LIMITED [GB/GB]; PsiOxus House, 4-10 The Quadrant, Barton Lane, Abingdon, Oxfordshire OX14 3YS (GB). (72) Inventors: CHAMPION, Brian, Robert; PsiOxus Ther- apeutics Ltd, PsiOxus House, 4-10 The Quadrant, Barton Lane, Abingdon, Oxfordshire OX14 3YS (GB). BROWN, Alice, Claire, Noel; PsiOxus Therapeutics Ltd, PsiOxus House, 4-10 The Quadrant, Barton Lane, Abingdon, Ox- fordshire OX14 3YS (GB). FREEDMAN, Joshua, David; 83 Manor Road, Chigwell IG7 5PH (GB). FISHER, Kerry, David; 11 Cassington Road Eynsham, Witney OX29 4LH (GB). SEYMOUR, Leonard, William; 5 Workhouse Yard Chapel Hill, Wootton by Woodstock OX20 1YD (GB). (74) Agent: STERLING IP LTD; Orion House, Bessemer Road, Welwyn Garden City, UNITED KINGDOM AL7 1HH (GB). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, (54) Title: ADENOVIRUS ARMED WITH BISPECIFIC T CELL ENGAGER (BITE) Figure 31 -N- With T-cells added Uninfected .4 6 EnN.: -CAN-ControtBITE EnAci.- Cti,V-Er.) ;A111:31TE EnAd-SA-EpGA;4;i3iTE co O (57) : A modified adenovirus, in particular Enadenotucirev (EnAd), armed with at least two bispecific T cell engager (BiTE) co each comprising at least two binding domains, wherein at least one of the domains is specific for a surface antigen on an immune cell of interest, such as a T-cell of interest. Also provided are a composition, such as a pharmaceutical formulation comprising the virus, O use of the virus and virus formulations for treatment, such as in the treatment of cancer. The disclosure also extends to processes for preparing the virus. C [Continued on next page] WO 2018/041827 Al MIDEDIMOMOIDEIREEMOOVIVHEIDIDEBER OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: with international search report (Art. 21(3)) with sequence listing part of description (Rule 5.2(a))
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1614607.8A GB201614607D0 (en) | 2016-08-29 | 2016-08-29 | Modified adenovirus |
GBGB1700663.6A GB201700663D0 (en) | 2017-01-13 | 2017-01-13 | Modified adenovirus |
GBGB1706219.1A GB201706219D0 (en) | 2017-04-19 | 2017-04-19 | Modified adenovirus |
GBGB1713765.4A GB201713765D0 (en) | 2017-08-28 | 2017-08-28 | Modified adenovirus |
PCT/EP2017/071655 WO2018041827A1 (en) | 2016-08-29 | 2017-08-29 | Adenovirus armed with bispecific t cell engager (bite) |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201901716TA true SG11201901716TA (en) | 2019-03-28 |
Family
ID=59923381
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201901716TA SG11201901716TA (en) | 2016-08-29 | 2017-08-29 | Adenovirus armed with bispecific t cell engager (bite) |
SG11201901715UA SG11201901715UA (en) | 2016-08-29 | 2017-08-29 | Adenovirus armed with bispecific t cell engager (bite) |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201901715UA SG11201901715UA (en) | 2016-08-29 | 2017-08-29 | Adenovirus armed with bispecific t cell engager (bite) |
Country Status (17)
Country | Link |
---|---|
US (2) | US20190194690A1 (en) |
EP (3) | EP4273252A3 (en) |
JP (3) | JP2019532621A (en) |
KR (2) | KR102491752B1 (en) |
CN (2) | CN110214025A (en) |
AU (1) | AU2017320776A1 (en) |
BR (1) | BR112019003866A2 (en) |
CA (2) | CA3033267A1 (en) |
CL (1) | CL2019000510A1 (en) |
CO (1) | CO2019002371A2 (en) |
IL (2) | IL264902B2 (en) |
MX (1) | MX2019002328A (en) |
MY (1) | MY197324A (en) |
PH (1) | PH12019500436A1 (en) |
SG (2) | SG11201901716TA (en) |
WO (2) | WO2018041838A1 (en) |
ZA (1) | ZA201900644B (en) |
Families Citing this family (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11053316B2 (en) | 2013-01-14 | 2021-07-06 | Xencor, Inc. | Optimized antibody variable regions |
US9605084B2 (en) | 2013-03-15 | 2017-03-28 | Xencor, Inc. | Heterodimeric proteins |
US10968276B2 (en) | 2013-03-12 | 2021-04-06 | Xencor, Inc. | Optimized anti-CD3 variable regions |
AU2014205086B2 (en) | 2013-01-14 | 2019-04-18 | Xencor, Inc. | Novel heterodimeric proteins |
US10858417B2 (en) | 2013-03-15 | 2020-12-08 | Xencor, Inc. | Heterodimeric proteins |
CA2927968C (en) | 2013-10-25 | 2023-02-21 | Psioxus Therapeutics Limited | Oncolytic adenoviruses armed with heterologous genes |
EP3954713A3 (en) | 2014-03-28 | 2022-03-30 | Xencor, Inc. | Bispecific antibodies that bind to cd38 and cd3 |
CA2967426A1 (en) | 2014-11-26 | 2016-06-02 | Xencor, Inc. | Heterodimeric antibodies that bind cd3 and tumor antigens |
US10259887B2 (en) | 2014-11-26 | 2019-04-16 | Xencor, Inc. | Heterodimeric antibodies that bind CD3 and tumor antigens |
BR112017011166A2 (en) | 2014-11-26 | 2018-02-27 | Xencor, Inc. | heterodimeric antibodies that bind to cd3 and cd38 |
PT3288573T (en) | 2015-04-30 | 2020-03-25 | Psioxus Therapeutics Ltd | Oncolytic adenovirus encoding a b7 protein |
EP3387013B1 (en) | 2015-12-07 | 2022-06-08 | Xencor, Inc. | Heterodimeric antibodies that bind cd3 and psma |
AU2016372576A1 (en) | 2015-12-17 | 2018-06-21 | Psioxus Therapeutics Limited | Virus encoding an anti-TCR-complex antibody or fragment |
MX2018015592A (en) | 2016-06-14 | 2019-04-24 | Xencor Inc | Bispecific checkpoint inhibitor antibodies. |
CA3029328A1 (en) | 2016-06-28 | 2018-01-04 | Xencor, Inc. | Heterodimeric antibodies that bind somatostatin receptor 2 |
GB201713765D0 (en) | 2017-08-28 | 2017-10-11 | Psioxus Therapeutics Ltd | Modified adenovirus |
WO2019125732A1 (en) | 2017-12-19 | 2019-06-27 | Xencor, Inc. | Engineered il-2 fc fusion proteins |
WO2019133847A1 (en) * | 2017-12-29 | 2019-07-04 | Oncorus, Inc. | Oncolytic viral delivery of therapeutic polypeptides |
AU2019247415A1 (en) * | 2018-04-04 | 2020-10-22 | Xencor, Inc. | Heterodimeric antibodies that bind fibroblast activation protein |
EP3781130A4 (en) * | 2018-04-11 | 2022-01-26 | Precision Molecular Inc. | Therapeutic constructs for treating cancer |
AU2019256529A1 (en) | 2018-04-18 | 2020-11-26 | Xencor, Inc. | TIM-3 targeted heterodimeric fusion proteins containing IL-15/IL-15Ra Fc-fusion proteins and TIM-3 antigen binding domains |
CA3097593A1 (en) | 2018-04-18 | 2019-10-24 | Xencor, Inc. | Pd-1 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and pd-1 antigen binding domains and uses thereof |
EP3847186A4 (en) * | 2018-09-05 | 2022-05-18 | Memorial Sloan Kettering Cancer Center | Pleural effusion-based methods for assessing immunoresponsive cell activity |
JP2022503959A (en) | 2018-10-03 | 2022-01-12 | ゼンコア インコーポレイテッド | IL-12 heterodimer FC-fusion protein |
CN109709341B (en) * | 2019-01-17 | 2020-12-15 | 浙江大学 | Biomarkers for the second subtype of osteoarthritis and uses |
BR112021015907A2 (en) * | 2019-02-20 | 2021-11-03 | Res Institute At Nationwide Childrens Hospital | Virus-encoded, regulatable cancer-targeting t (catvert) or nk (catvern) cell ligands |
WO2020180726A1 (en) | 2019-03-01 | 2020-09-10 | Xencor, Inc. | Heterodimeric antibodies that bind enpp3 and cd3 |
KR102503349B1 (en) | 2019-05-14 | 2023-02-23 | 프로벤션 바이오, 인코포레이티드 | Methods and compositions for preventing type 1 diabetes |
WO2021231976A1 (en) | 2020-05-14 | 2021-11-18 | Xencor, Inc. | Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3 |
AU2021329378A1 (en) | 2020-08-19 | 2023-03-23 | Xencor, Inc. | Anti-CD28 compositions |
EP4217738A1 (en) * | 2020-09-27 | 2023-08-02 | Genentech, Inc. | High throughput multiparametric immune cell engager screening assay |
EP4247850A1 (en) | 2020-11-20 | 2023-09-27 | Simcere Innovation, Inc. | Armed dual car-t compositions and methods for cancer immunotherapy |
WO2022148736A1 (en) * | 2021-01-05 | 2022-07-14 | Transgene | Vectorization of muc1 t cell engager |
GB202102049D0 (en) | 2021-02-13 | 2021-03-31 | Psioxus Therapeutics Ltd | Viruses |
EP4305067A1 (en) | 2021-03-09 | 2024-01-17 | Xencor, Inc. | Heterodimeric antibodies that bind cd3 and cldn6 |
WO2022192586A1 (en) | 2021-03-10 | 2022-09-15 | Xencor, Inc. | Heterodimeric antibodies that bind cd3 and gpc3 |
CN115161293A (en) * | 2021-04-01 | 2022-10-11 | 南京惟亚德生物医药有限公司 | Oncolytic vaccinia virus for coding bispecific T cell adaptor and preparation method and application thereof |
WO2023161457A1 (en) | 2022-02-27 | 2023-08-31 | Evobright Gmbh | Bispecific antibodies against cd277 and a tumor-antigen |
WO2024022602A1 (en) | 2022-07-28 | 2024-02-01 | Akamis Bio Ltd | Virus encoding transgenes to complement cellular therapy |
WO2024047114A1 (en) * | 2022-08-31 | 2024-03-07 | Universität Zürich | Adenoviral-based in situ delivery of bispecific t cell engagers |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
GB9113120D0 (en) | 1991-06-18 | 1991-08-07 | Kodak Ltd | Photographic processing apparatus |
US5587299A (en) | 1994-04-20 | 1996-12-24 | Memorial Sloan-Kettering Cancer Center | Isolated nucleic acid molecule coding for fibroblast activation protein alpha and uses thereof |
WO2005003169A2 (en) | 2003-07-01 | 2005-01-13 | Celltech R & D Limited | Modified antibody fab fragments |
GB0315457D0 (en) | 2003-07-01 | 2003-08-06 | Celltech R&D Ltd | Biological products |
GB0315450D0 (en) | 2003-07-01 | 2003-08-06 | Celltech R&D Ltd | Biological products |
KR101229731B1 (en) * | 2003-10-16 | 2013-03-07 | 암젠 리서치 (뮌헨) 게엠베하 | Multispecific deimmunized cd3-binders |
GB0411186D0 (en) | 2004-05-19 | 2004-06-23 | Celltech R&D Ltd | Biological products |
CA2836987C (en) | 2004-05-26 | 2016-07-05 | Psioxus Therapeutics Limited | Chimeric adenoviruses for use in cancer treatment |
US7550296B2 (en) | 2004-12-01 | 2009-06-23 | Bayer Schering Pharma Ag | Generation of replication competent viruses for therapeutic use |
CA2673520A1 (en) | 2006-12-22 | 2008-07-03 | Bayer Schering Pharma Aktiengesellschaft | Generation of oncolytic adenoviruses and uses thereof |
EP2195341B1 (en) | 2007-09-26 | 2017-03-22 | UCB Biopharma SPRL | Dual specificity antibody fusions |
HUE033438T2 (en) | 2008-09-26 | 2017-11-28 | Ucb Biopharma Sprl | Biological products |
RU2547600C2 (en) | 2008-10-01 | 2015-04-10 | Эмджен Рисерч (Мьюник) Гмбх | Pscaxcd3, cd19xcd3, c-metxcd3, endosialin xcd3, epcamxcd3, igf-1rxcd3 or fap-alpha xcd3 bispecific single-chain antibody with inter-species specificity |
CA2776037A1 (en) | 2009-10-02 | 2011-04-07 | Ludwig Institute For Cancer Research Ltd | Anti-fibroblast activation protein antibodies and methods and uses thereof |
WO2014138314A1 (en) * | 2013-03-05 | 2014-09-12 | Baylor College Of Medicine | Oncolytic virus |
CN105592788A (en) * | 2013-03-06 | 2016-05-18 | 塞罗拉公司 | Form factors for the multi-modal physiological assessment of brain health |
CA2927968C (en) * | 2013-10-25 | 2023-02-21 | Psioxus Therapeutics Limited | Oncolytic adenoviruses armed with heterologous genes |
GB201406608D0 (en) * | 2014-04-12 | 2014-05-28 | Psioxus Therapeutics Ltd | Virus |
EP3186366A2 (en) * | 2014-08-27 | 2017-07-05 | Psioxus Therapeutics Limited | A process for the production of adenovirus |
CN107406859A (en) * | 2015-03-17 | 2017-11-28 | 倾斜生物医疗公司 | The oncolytic adenovirus of encoding bispecific antibody and relative method and purposes |
-
2017
- 2017-08-29 SG SG11201901716TA patent/SG11201901716TA/en unknown
- 2017-08-29 IL IL264902A patent/IL264902B2/en unknown
- 2017-08-29 KR KR1020227026101A patent/KR102491752B1/en active IP Right Grant
- 2017-08-29 CA CA3033267A patent/CA3033267A1/en not_active Abandoned
- 2017-08-29 CN CN201780057768.4A patent/CN110214025A/en active Pending
- 2017-08-29 IL IL303187A patent/IL303187A/en unknown
- 2017-08-29 US US16/329,098 patent/US20190194690A1/en active Pending
- 2017-08-29 WO PCT/EP2017/071674 patent/WO2018041838A1/en active Application Filing
- 2017-08-29 KR KR1020197008941A patent/KR102427563B1/en active IP Right Grant
- 2017-08-29 CN CN201780056486.2A patent/CN109862912A/en active Pending
- 2017-08-29 EP EP23170482.6A patent/EP4273252A3/en active Pending
- 2017-08-29 CA CA3034517A patent/CA3034517A1/en active Pending
- 2017-08-29 EP EP17771344.3A patent/EP3503919B1/en active Active
- 2017-08-29 JP JP2019507924A patent/JP2019532621A/en active Pending
- 2017-08-29 SG SG11201901715UA patent/SG11201901715UA/en unknown
- 2017-08-29 EP EP17771343.5A patent/EP3503918B1/en active Active
- 2017-08-29 US US16/329,125 patent/US20190233536A1/en active Pending
- 2017-08-29 AU AU2017320776A patent/AU2017320776A1/en active Pending
- 2017-08-29 JP JP2019532192A patent/JP7212620B2/en active Active
- 2017-08-29 WO PCT/EP2017/071655 patent/WO2018041827A1/en active Application Filing
- 2017-08-29 BR BR112019003866A patent/BR112019003866A2/en unknown
- 2017-08-29 MY MYPI2019000750A patent/MY197324A/en unknown
- 2017-08-29 MX MX2019002328A patent/MX2019002328A/en unknown
-
2019
- 2019-01-30 ZA ZA2019/00644A patent/ZA201900644B/en unknown
- 2019-02-26 CL CL2019000510A patent/CL2019000510A1/en unknown
- 2019-02-28 PH PH12019500436A patent/PH12019500436A1/en unknown
- 2019-03-14 CO CONC2019/0002371A patent/CO2019002371A2/en unknown
-
2022
- 2022-08-17 JP JP2022130173A patent/JP2022166209A/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201901716TA (en) | Adenovirus armed with bispecific t cell engager (bite) | |
SG11201805136TA (en) | Group b adenovirus encoding an anti-tcr-complex antibody or fragment | |
SG11201900480YA (en) | Anti-tim-3 antibodies | |
SG11201901548SA (en) | Anti-tim-3 antibodies and use thereof | |
SG11201807187XA (en) | Binding members to pd-l1 | |
SG11201808622SA (en) | Chimeric receptors to flt3 and methods of use thereof | |
SG11201908567UA (en) | Modified cyclic dinucleotide compounds | |
SG11201806322QA (en) | Maytansinoid derivatives, conjugates thereof, and methods of use | |
SG11201808125RA (en) | Methods for solid tumor treatment | |
SG11201906223TA (en) | Benzisothiazole, isothiazolo[3,4-b]pyridine, quinazoline, phthalazine, pyrido[2,3-d]pyridazine and pyrido[2,3-d]pyrimidine derivatives as kras g12c inhibitors for treating lung, pancreatic or colorectal cancer | |
SG11201903697WA (en) | Liver organoid compositions and methods of making and using same | |
SG11201907427YA (en) | Engineered transferrin receptor binding polypeptides | |
SG11201806419RA (en) | Anti-cd74 antibody conjugates, compositions comprising anti-cd74 antibody conjugates and methods of using anti-cd74 antibody conjugates | |
SG11201909963YA (en) | Methods for treating dravet syndrome | |
SG11201805709RA (en) | Anti-pro/latent myostatin antibodies and methods of use thereof | |
SG11201810628XA (en) | Nasal pharmaceutical compositions with a porous excipient | |
SG11201903889TA (en) | Crenolanib for treating flt3 mutated proliferative disorders associated mutations | |
SG11201810525XA (en) | Anti-gitr antibodies and uses thereof | |
SG11202000312UA (en) | Encapsulated polynucleotides and methods of use | |
SG11201807593TA (en) | Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers | |
SG11201909691WA (en) | Cementitious composite mat | |
SG11201900845YA (en) | Uses of il-13 antagonists for treating atopic dermatitis | |
SG11201901347UA (en) | Compositions and methods for cancer immunotherapy | |
SG11201407801VA (en) | Methods for use of mixed multifunctional surfaces for reducing aggregate content in protein preparations | |
SG11201805385QA (en) | Bromodomain and extra-terminal protein inhibitor combination therapy |